GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » EV-to-FCF

Biomea Fusion (Biomea Fusion) EV-to-FCF : -2.78 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biomea Fusion's Enterprise Value is $278.14 Mil. Biomea Fusion's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-99.96 Mil. Therefore, Biomea Fusion's EV-to-FCF for today is -2.78.

The historical rank and industry rank for Biomea Fusion's EV-to-FCF or its related term are showing as below:

BMEA' s EV-to-FCF Range Over the Past 10 Years
Min: -38.43   Med: 0   Max: 2.11
Current: -2.78

During the past 5 years, the highest EV-to-FCF of Biomea Fusion was 2.11. The lowest was -38.43. And the median was 0.00.

BMEA's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs BMEA: -2.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Biomea Fusion's stock price is $12.35. Biomea Fusion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.460. Therefore, Biomea Fusion's PE Ratio for today is At Loss.


Biomea Fusion EV-to-FCF Historical Data

The historical data trend for Biomea Fusion's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion EV-to-FCF Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -1.20 -2.18 -3.54

Biomea Fusion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -10.54 -6.30 -3.10 -3.54

Competitive Comparison of Biomea Fusion's EV-to-FCF

For the Biotechnology subindustry, Biomea Fusion's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's EV-to-FCF falls into.



Biomea Fusion EV-to-FCF Calculation

Biomea Fusion's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=278.138/-99.962
=-2.78

Biomea Fusion's current Enterprise Value is $278.14 Mil.
Biomea Fusion's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomea Fusion  (NAS:BMEA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biomea Fusion's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.35/-3.460
=At Loss

Biomea Fusion's share price for today is $12.35.
Biomea Fusion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biomea Fusion EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomea Fusion (Biomea Fusion) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Executives
Juan Pablo Frias officer: Chief Medical Officer 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc. 10 percent owner 59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m. director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle officer: Chief Financial Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust director C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann director, 10 percent owner, officer: President and COO 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler director, 10 percent owner, officer: CEO 726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc 10 percent owner 726 MAIN STREET, REDWOOD CITY CA 94063

Biomea Fusion (Biomea Fusion) Headlines

From GuruFocus